TNFSF10 and cancer: For example, targeted delivery of TRAIL to tumor sites failed due to rapid systemic clearance and physical barriers in the TME, which reduced the therapeutic dose level of available TRAIL to induce sufficient apoptosis in cancer cells [17,18].